Prolonged postoperative euglycemic diabetic ketoacidosis in a lung transplant recipient with preoperative SGLT2 inhibitor use
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were first approved by the Food& Drug Administration (FDA) in 2013 as a therapy to improve glycemic control in patients with type 2 diabetes mellitus (T2DM)1. With recent evidence suggesting decreased risk of death from cardiovascular causes as well as cardio- and renal-protective effects,2-10 the indications for SGLT2 inhibitor use have expanded to include patients with cardiovascular disease, systolic and diastolic heart failure, chronic kidney disease,11,12 as well as patients hospitalized for acute de novo or decompensated chronic heart failure, regardless of ejection fraction or concurrent diagnosis of T2DM after initial stabilization.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Christine H. Choi, Shivani Singh, Albert T. Cheung, Matthew Vanneman, Jai Madhok Tags: Case Report Source Type: research
More News: Anesthesia | Anesthesiology | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Heart Transplant | Kidney Transplant | Kidney Transplantation | Lung Transplant | SGLT2 Inhibitors | Sodium | Transplant Surgery | Transplants | Urology & Nephrology